Literature DB >> 23459194

Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma.

Cara J Westmark1, Crystal M Hervey, Elizabeth M Berry-Kravis, James S Malter.   

Abstract

Altered levels of amyloid β-protein precursor (AβPP) and/or amyloid beta (Aβ) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy. Thus, these proteins could serve as valuable blood-based biomarkers for assessing disease severity and pharmacological efficacy. We have observed significant differences in Aβ1-42 levels in human plasma dependent on the anticoagulant utilized during blood collection. Our data suggests that anticoagulants alter AβPP processing and that care needs to be used in comparing published studies that have not utilized the same blood collection methodology.

Entities:  

Keywords:  Alzheimer's disease; ELISA; amyloid beta; amyloid β-protein precursor; biomarker

Year:  2011        PMID: 23459194      PMCID: PMC3583344          DOI: 10.4172/2161-0460.1000101

Source DB:  PubMed          Journal:  J Alzheimers Dis Parkinsonism


  15 in total

1.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

2.  High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression.

Authors:  Deborah K Sokol; Demao Chen; Martin R Farlow; David W Dunn; Bryan Maloney; Jennifer A Zimmer; Debomoy K Lahiri
Journal:  J Child Neurol       Date:  2006-06       Impact factor: 1.987

3.  Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Authors:  Pankaj D Mehta; George Capone; Amy Jewell; Robert L Freedland
Journal:  J Neurol Sci       Date:  2007-02-02       Impact factor: 3.181

4.  CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Authors:  Guido Alves; Kolbjørn Brønnick; Dag Aarsland; Kaj Blennow; Henrik Zetterberg; Clive Ballard; Martin Wilhelm Kurz; Ulf Andreasson; Ole-Bjørn Tysnes; Jan Petter Larsen; Ezra Mulugeta
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-14       Impact factor: 10.154

5.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

Authors:  Marieke van Oijen; Albert Hofman; Holly D Soares; Peter J Koudstaal; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-08       Impact factor: 44.182

6.  Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis.

Authors:  Antoinette R Bailey; Brian N Giunta; Demian Obregon; William V Nikolic; Jun Tian; Cyndy D Sanberg; Danielle T Sutton; Jun Tan
Journal:  Int J Clin Exp Med       Date:  2008-10-15

7.  Performance characteristics of plasma amyloid-beta 40 and 42 assays.

Authors:  Olivia I Okereke; Weiming Xia; Michael C Irizarry; Xiaoyan Sun; Wei Q Qiu; Anne M Fagan; Pankaj D Mehta; Bradley T Hyman; Dennis J Selkoe; Francine Grodstein
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Authors:  Oskar Hansson; Henrik Zetterberg; Eugeen Vanmechelen; Hugo Vanderstichele; Ulf Andreasson; Elisabet Londos; Anders Wallin; Lennart Minthon; Kaj Blennow
Journal:  Neurobiol Aging       Date:  2008-05-19       Impact factor: 4.673

9.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.

Authors:  Nicole Schupf; Bindu Patel; Deborah Pang; Warren B Zigman; Wayne Silverman; Pankaj D Mehta; Richard Mayeux
Journal:  Arch Neurol       Date:  2007-07

10.  FMRP mediates mGluR5-dependent translation of amyloid precursor protein.

Authors:  Cara J Westmark; James S Malter
Journal:  PLoS Biol       Date:  2007-03       Impact factor: 8.029

View more
  5 in total

1.  Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.

Authors:  Li Zhou; Jianxu Liu; Dong Dong; Chunsheng Wei; Rui Wang
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 2.  Fragile X and APP: a Decade in Review, a Vision for the Future.

Authors:  Cara J Westmark
Journal:  Mol Neurobiol       Date:  2018-09-17       Impact factor: 5.590

3.  Developing BACE-1 inhibitors for FXS.

Authors:  Cara J Westmark; Elizabeth M Berry-Kravis; Chrysanthy Ikonomidou; Jerry C P Yin; Luigi Puglielli
Journal:  Front Cell Neurosci       Date:  2013-05-28       Impact factor: 5.505

4.  Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome.

Authors:  Richard D McLane; Lauren M Schmitt; Ernest V Pedapati; Rebecca C Shaffer; Kelli C Dominick; Paul S Horn; Christina Gross; Craig A Erickson
Journal:  Front Integr Neurosci       Date:  2019-09-03

Review 5.  Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.

Authors:  C J Westmark; D K Sokol; B Maloney; D K Lahiri
Journal:  Mol Psychiatry       Date:  2016-08-30       Impact factor: 15.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.